Abstract. Cytotoxic T-lymphocyte activation and extension of the cell life span is necessary in order to enable immunotherapy to perform effectively against cancer. In the present study, mucin 1 (MUC1)-stimulated human mononuclear cells (M1SHMCs) were costimulated with bead-attached monoclonal antibodies specific for cluster of differentiation (CD)3 and CD28 receptors. The study was undertaken to determine whether costimulation was capable of enhancing the killing of cancer cells in vitro and of protecting non-obese diabetic severe combined immunodeficient mice from tumor development. Lysis of MCF-7 tumor cells by M1SHMCs was reduced following costimulation with anti-CD3 and anti-CD28. Furthermore, costimulation with anti-CD3 and anti-CD28 eliminated the protective effects of M1SHMCs on MCF-7 breast cancer cell growth in the non-obese diabetic severe combined immunodeficient mice. The present study suggested that costimulation with anti-CD3 and anti-CD28 is not advisable following antigen activation of lymphocytes under the conditions used here. Using a lower anti-CD3/CD28 bead to T-cell ratio may prevent immune suppression, however, further studies are required to support this hypothesis.
IntroductionCytotoxic T-lymphocyte (CTL) activation and extension of the cell life span are necessary in order to enable immunotherapy to perform effectively against cancer cells (1). CTLs are activated via the T-cell receptor (TCR; signal one) (2), which induces the proliferation of CTLs. Engagement of a second receptor, cluster of differentiation 28 (CD28; signal two), by ligands on antigen-presenting cells, is required to prevent anergy and the apoptosis of CTLs (3). This results in extension of the CTL lifespan. CTLs may be activated via the CD3 receptor [a component of the TCR (2)] and the CD28 receptor using monoclonal antibodies specific for their respective receptors (4). In order to obtain an adequate number of CTLs for the effective performance of immunotherapy, costimulation with anti-CD3 and anti-CD28 has been utilized (5). Costimulated lymphocytes cells have been demonstrated to exhibit logarithmic growth and inhibit apoptosis via enhanced cytotoxicity for the targeting of tumor cells (6). The present study aimed to determine whether the mucin 1 (MUC1)-stimulated human mononuclear cells (M1SHMCs) of breast cancer patients would demonstrate expanded levels of growth without compromising their ability to kill cancer cells when costimulated with anti-CD3 and anti-CD28.
Materials and methods
MUC1-variable number tandem repeat 1 (VNTR1) peptide.GSTAPPAHGVTSAPDTRPAP (7) peptide was synthesized by American Peptide Co., Inc., (Sunnyvale, CA, USA) and Novartis International AG (Basel, Switzerland).Anti-CD3/CD28 antibody beads. Anti-CD28 antibodies were obtained from Murine Hybridoma 9.3 (8), which was a gift from Professor John Hansen (University of Washington, Seattle, USA). Dynabeads ® M-450 Tosylactivated (Thermo Fisher Scientific, Inc., Waltham, MA, USA) are superparamagnetic polystyrene beads, which were activated usi...